Next, bolus insulin, restarted with altered formulations comprised of regular human insulin or insulin lispro, inhibited neither postprandial hyperglycemia nor morning hypoglycemia. (insulin aspart regular human insulin insulin lispro) proved to be ineffective. After several therapeutic trials, cessation of exogenous insulin and addition of mitiglinide to liraglutide with voglibose finally attenuated glycemic fluctuations with increased postprandial insulin secretion. Continuous glucose monitoring revealed improvement of morning hypoglycemia and postprandial hyperglycemia with smaller mean amplitude of glycemic excursion. Therefore, Rabbit polyclonal to MTH1 compared to exogenously injected insulin, endogenously secreted insulin directly and rapidly acts on hepatocytes and suppresses postprandial glucose output. Conclusions Proper enhancement of postprandial endogenous insulin aimed at suppressing postprandial glucose output without stimulating excessive glucose uptake in the periphery is usually potentially useful for treating diabetes with insulin antibody-induced glycemic instability. Keywords: Hypoglycemia, Insulin antibody, Insulin autoimmune syndrome, Postprandial Istaroxime endogenous insulin Background Insulin autoimmune syndrome (IAS), or Hiratas disease, is usually characterized by the presence of insulin-binding autoantibodies in patients who have never been exposed to exogenous insulin [1]. Scatchard plot analysis has revealed that this type of insulin autoantibody has high binding capacity and low affinity [1], thereby causing amazing hyperinsulinemia and fasting or late postprandial hypoglycemia. Eating small meals and -glucosidase treatment to decrease insulin secretion are recommended to suppress the hyperinsulinemia [2]. Exogenously injected insulin can also trigger the production of insulin antibodies, but these antibodies mostly do not disturb glycemic controls [3]. However, it has recently been reported that insulin antibodies occasionally result in characteristics similar to those due to Istaroxime insulin autoantibodies in IAS patients, including marked glycemic fluctuations with postprandial hyperglycemia and fasting hypoglycemia [4C6]. In these patients, changing insulin formulations is usually occasionally effective for decreasing insulin antibody levels and improving glycemic control [7]. However, we experienced an insulin-treated patient with the IAS-like insulin antibodies whose glycemic fluctuations were not reduced by altering insulin formulations. We speculated that subcutaneous administration of exogenous insulin has two potential disadvantages compared to endogenous insulin secreted from pancreatic cells. First, exogenously injected insulin persisting at subcutaneous sites may have more chances to be captured by insulin antibodies. Second, endogenously secreted insulin directly and rapidly acts on hepatocytes and suppresses postprandial glucose output from the liver, while subcutaneously injected insulin may exacerbate hypoglycemia due to exerting preferential actions on muscle and excess fat tissues. Based on these ideas, we switched the treatment from insulin injections to mitiglinide with liraglutide and voglibose with the aim of enhancing postprandial secretion of endogenous insulin, and finally attenuated the glycemic fluctuations. Case presentation A 66-year-old man with a 27-12 months history of diabetes was hospitalized because of severe morning hypoglycemia and postprandial hyperglycemia. At age 39, he had shown symptoms of polyuria and was diagnosed as having type 2 Istaroxime diabetes. At the initial treatment, an allergic skin reaction to porcine insulin occurred, requiring a switch from insulin to oral hypoglycemic agents. He often missed clinic visits, which contributed to inadequate glycemic control. He was after that hospitalized for glycemic control (HbA1c: 11.7% (104?mmol/mol)) when he was 54?years of age. In this hospitalization, his fasting serum C-peptide level was 1.41?ng/mL and blood sugar amounts were promptly improved by diet treatment with dental hypoglycemic real estate agents (sulfonylurea and -glucosidase). He underwent photocoagulation therapy for proliferative-diabetic retinopathy and his creatinine level was 1.0?mg/dL as of this ideal period. At age group 56, premixed human being insulin 30/70 was given after an bout of diabetic ketoacidosis with subcutaneous abscesses, but, once again, because of his poor adherence primarily, his glycemic control got continued to be inadequate with HbA1c of 10 around.0% (86?mmol/mol). After that, an entire cessation of treatment for 3 years led to a designated HbA1c boost to 18.9% (183?mmol/mol). At this time (61?years of age), multiple daily insulin therapy using insulin analogs, we.e. aspart before every detemir and food before bedtime, was released and his.